Rebecca Anne Miksad MD MMS, MPH (She/Her)
[Pronunciation: Re-be-cah Mik-sad]
Cancer Genetics/Cancer Risk Assessment, Gastrointestinal Cancer, Clinical Informatics
Chief Medical Officer, Color Health | Associate Professor, Boston University School of Medicine | Attending Physician, Gastrointestinal Cancer and Head, High Risk Cancer Genetics, Boston Medical Center
Join to view full profile
830 Harrison Ave# MoakleyBoston, MA 02118
Phone+1 617-638-6428
Dr. Miksad is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Rebecca Miksad is an experienced oncologist based in Boston, MA, with subspecialties in cancer genetics, cancer risk assessment, gastrointestinal cancer, and clinical informatics. She completed her education with a fellowship in Hematology and Medical Oncology at Beth Israel Deaconess Medical Center and holds an MPH in Clinical Effectiveness from the Harvard School of Public Health. Dr. Miksad is the Chief Medical Officer at Color Health and holds positions as an Associate Professor at Boston University and an Assistant Professor at Harvard Medical School. Additionally, she founded MiksadMD Consulting and leads the High Risk Cancer Genetics Clinic at Boston Medical Center. Her research is focused on cancer genetics, hepatocellular carcinoma, cholangiocarcinoma, and she has authored several publications in esteemed journals. She has been involved in clinical trials on esophageal, colorectal, pancreatic, and liver cancers. Dr. Miksad has received multiple certifications for CMS Meaningful Use and has served as a Senior Scientist at Massachusetts General Hospital.
Clinical Expertise
- Gastrointestinal cancer, Hepatocellular carcinoma, Cholangiocarcinoma, Hematologic oncology, Hereditary nonpolyposis colon cancer, Cancer genetics, Lynch syndrome, Neuroendocrine tumors, Genetics, Hereditary nonpolyposis colorectal cancer syndrome, Clinical research, Telemedicine, BRCA gene positivity, Pancreatic ductal carcinoma, Drug development, Combined modality therapy, Medical oncology, Healthcare technology/informatics, Gastrointestinal oncology, Helathcare delivery, Tumor imaging, Bile Duct Neoplasms, Gallbladder Neoplasms
Education & Training
Harvard Medical SchoolMMS, Translational Research, 2009 - 2011
Harvard T.H. Chan School of Public HealthMPH, Clinical Effectiveness, 2008
Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 2004 - 2007
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2001 - 2004
Weill Cornell MedicineClass of 2001
Certifications & Licensure
NM State Medical License 2025 - 2029
IL State Medical License 2025 - 2029
UT State Medical License 2025 - 2028
DC State Medical License 2025 - 2028
TN State Medical License 2025 - 2028
RI State Medical License 2025 - 2028
HI State Medical License 2025 - 2028
American Board of Internal Medicine Medical Oncology- Join now to see all
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Online Medical Record, Beth Israel Deaconess Medical Center, 2012, 2014-2017
- CMS Meaningful Use Stage 2 Certification Online Medical Record, Beth Israel Deaconess Medical Center, 2012, 2014-2017
- CMS Meaningful Use Stage 2 Certification Quality Data Center, Massachusetts eHealth Collaborative (MAeHC), 2012, 2014-2017
Clinical Trials
Publications & Presentations
PubMed
- 4 citationsBench to Budget: Integrated Evidence Generation for Medications.Sebastian Schneeweiss, Rebecca Miksad
Clinical Pharmacology and Therapeutics. 2025-04-01 - Evaluating Cancer Screening in the Era of Advanced Causal Inference Methods: Innovation, Adherence, and Health Equity Considerations.Rebecca A Miksad, Somnath Sarkar
JCO Clinical Cancer Informatics. 2025-01-01 - 20 citationsSystemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors.Maureen E Canavan, Xiaoliang Wang, Mustafa S Ascha, Rebecca A Miksad, Timothy N Showalter
JAMA Oncology. 2024-07-01
Press Mentions
The Fight to Keep Parenthood PossibleFebruary 28th, 2025- Cancer's Hidden Cost Burden Strains Patients and Health Systems: ReportJanuary 27th, 2025
- Color Health Builds Out Virtual Cancer Clinic, Taking Aim at Employer, Health Plan MarketOctober 18th, 2024
Grant Support
- Optimizing Localized Therapy For Primary Liver Cancer: A Clinical Trial And ModelNational Cancer Institute2009–2011
Professional Memberships
- Member
External Links
- LinkedInhttps://www.linkedin.com/in/rebeccamiksadmd/
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
